@article {Hamlin133, author = {P J Hamlin and L Warren and S M Everett}, title = {Establishing a biologics service for patients with inflammatory bowel disease}, volume = {2}, number = {3}, pages = {133--139}, year = {2011}, doi = {10.1136/fg.2010.003558}, publisher = {British Medical Journal Publishing Group}, abstract = {The use of anti-TNF therapy in the management of Crohn{\textquoteright}s disease and, to a lesser extent ulcerative colitis, is increasing. This article aims to discuss the practicalities of establishing a biologics service for patients with inflammatory bowel disease. Current guidelines on the use of these drugs are reviewed followed by a discussion on the choice of which anti-TNF agent to use based on costs and patient choice. A model for the initiation, administration, monitoring and assessment of patients receiving anti-TNF therapy is proposed. The need for a national biologics registry is highlighted in the summary.}, issn = {2041-4137}, URL = {https://fg.bmj.com/content/2/3/133}, eprint = {https://fg.bmj.com/content/2/3/133.full.pdf}, journal = {Frontline Gastroenterology} }